Robust billing and coding system needed for psychedelic therapies

When psychedelic therapies begin to gain regulatory approval, they will need to be incorporated into the medical billing and coding system in a way that ensures equitable patient access. A new article that presents a robust medical billing and coding strategy is published in the inaugural issue of Psychedelic Medicine. Click here to read the article now.

Brian Barnett, from the Cleveland Clinic, coauthored the article titled “Psychedelic Medicine’s Future Depends on Proactive Development of a Robust Medical Billing and Coding Strategy.” The authors note that investigational psychedelic therapies are likely to begin gaining regulatory approval as medical treatments in the U.S. within the next 2 years. If approved, equitable patient access will depend on the incorporation of these novel treatments into the medical billing and coding system. The authors propose that the development of de novo billing codes is the best approach for addressing psychedelic therapy reimbursement concerns. Several factors make psychedelic therapy, “particularly vulnerable to development of billing codes that undervalue the complexity of its delivery,” state the authors. 

Also in the premier issue of Psychedelic Medicine, Meghan Hibicke, Hannah Kramer, and Charles Nichols, from LSU Health Sciences Center, used adult female rats subjected to adolescent chronic restraint stress (aCRS) to investigate the effects of psilocybin on forced swim test and object pattern separation behaviors 5 weeks after a single administration. The aCRS paradigm uses mild developmental stress to elicit depressive-like characteristics that persist for many weeks after the final stress event. The forced swim test challenges rats with inescapable adversity. Antidepressants selectively increase active cooping in the forced swim test. Impaired pattern separation is another characteristic of depression. Antidepressants rescue cognitive function relevant to patter separation.

“A single dose of psilocybin produced long-lasting normalization of pattern separation and forced swim test activities in aCRS rats, but without persistent increases in mRNA of a panel of genes relevant to synaptic density across several brain regions,” concluded the investigators. “Although there is considerable evidence that psychedelics initiate an acute period of synaptic plasticity, our results may indicate the functional plasticity, not structural plasticity, underlies the persistent antidepressant-like effects of psilocybin in our model.”

About the Journal
Psychedelic Medicine is the first peer-reviewed journal to publish original research papers on every aspect of psychedelic medicine, including basic science, clinical, and translational research, as well as medical applications. This journal provides a vital resource for clinicians and patients alike who are invested in the potential efficacy of psychedelic drugs currently undergoing research in preclinical and clinical studies as an alternative or supplement to traditionally manufactured pharmaceuticals to treat depression, anxiety, addiction, demoralization, and other mental health conditions. Visit the Psychedelic Medicine website to learn more.

About the Publisher
Mary Ann Liebert, Inc., publishers is known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research. A complete list of the firm’s more than 100 journals and books is available on the Mary Ann Liebert, Inc., publishers website.